Xencor Inc — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Xencor reported Q3 2026 revenue of $116.5M (vs. $21.0M in Q3 2025), driven primarily by $52.5M Alexion settlement payment received in August 2026 and milestone revenue from Astellas ($25.0M triggered by ASP2138 Phase 3 initiation). Net income was $39.4M ($0.50/share diluted) vs. net loss of $6.0M in Q3 2025. Cash position decreased to $555.7M (Sept 30, 2026) from $610.8M (Dec 31, 2025). Lead program XmAb819 demonstrated 45.5% confirmed objective response rate in advanced clear cell renal cell carcinoma at 400 mcg/kg IV dose (n=11); company plans Phase 3 initiation by end of 2027 and FDA engagement on accelerated approval pathway in H1 2027. Company guided to $480-500M cash at 2026 year-end and sufficient runway into 2029.
Why this rating
Strong clinical efficacy data for lead asset XmAb819 and major partnership milestone payments offset by non-recurring revenue items. Moderate positive impact relative to ~$556M market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.